KOL | Alistair WheelerPresent address: Spyryx Biosciences, Inc., Durham, NC, USA | Sunovion Pharmaceuticals, Inc., Marlborough, Massachusetts. | Sunovion Pharmaceuticals Inc., Marlborough, MA, USA ... |
KOL Resume for Alistair Wheeler
| Year | |
|---|---|
| 2017 | Present address: Spyryx Biosciences, Inc., Durham, NC, USA Sunovion Pharmaceuticals, Inc., Marlborough, Massachusetts. |
| 2014 | From the Department of Pulmonary Diseases and Critical Care Medicine (Dr Donohue), The University of North Carolina at Chapel Hill, Chapel Hill, NC; the Section of Pulmonary, Critical Care, and Sleep Medicine (Dr Hanania), Baylor College of Medicine, Houston, TX; the Division of Pulmonary, Critical Care, and Sleep Medicine (Dr Make), National Jewish Health, University of Colorado Denver School of Medicine, Denver, CO; the Department of Pulmonary, Critical Care, Allergy, and Immunologic Medicine (Dr Miles), Wake Forest School of Medicine, Winston-Salem, NC; the Department of Medicine (Dr Mahler), Geisel School of Medicine at Dartmouth, Hanover, NH; the Research & Development Division (Ms Curry, Mr Tosiello, and Dr Wheeler), Sunovion Pharmaceuticals Inc, Marlborough, MA; and the Department of Medicine/Division of Pulmonary and Critical Care Medicine (Dr Tashkin), David Geffen School of Medicine at UCLA, Los Angeles, CA. |
Alistair Wheeler: Influence Statistics
| Concept | World rank |
|---|---|
| glycopyrrolate maintenance | #3 |
| nebulizer phase | #4 |
| 7 glycopyrrolate | #4 |
| 28day parallelgroup | #4 |
| glycopyrrolate aclidinium bromide | #4 |
| nct02038829 | #4 |
| bid fev1 | #4 |
| 7day crossover | #4 |
| eflow nebulizer golden | #4 |
| golden 6 studies | #4 |
| eflow phase | #4 |
| golden glycopyrrolate | #4 |
| 125 μg bid | #4 |
| chronic obstructive golden | #4 |
| eflow closed nebulizer | #5 |
| simulated glycopyrrolate | #5 |
| aerosols glycopyrrolate | #5 |
| copd eflow | #5 |
| iii golden | #5 |
| eflow copd | #5 |
| nonnebulized samples | #5 |
| acceptable impurity profile | #5 |
| eflow glycopyrrolate aerosols | #5 |
| eflow vmd | #5 |
| glycopyrrolate aerosols | #5 |
| glycopyrrolate concentration | #5 |
| nebulized vmd | #5 |
| vmd nebulized | #5 |
| vmd eflow | #5 |
| nebulizer glycopyrrolate | #5 |
| glycopyrrolate nebulizers | #5 |
| nebulization outputs | #5 |
| copd glycopyrrolate eflow | #5 |
| nebulized nebulization | #5 |
| nebulized nebulization time | #5 |
| subjects glycopyrrolate | #6 |
| golden 6 | #6 |
| teaes glycopyrrolate | #6 |
| eflow treatment | #6 |
| eflow moderate | #6 |
| eflow nebulizer subjects | #6 |
| diseases glycopyrrolate | #6 |
| teaes copd | #6 |
| glycopyrrolate tolerated | #6 |
| improvements trough fev1 | #6 |
| glycopyrrolate mace | #6 |
| tiotropium 48 weeks | #6 |
| mace glycopyrrolate | #6 |
| simulated nebulizer | #7 |
| glycopyrrolate solution | #7 |
Open the FULL List in Excel | |
Prominent publications by Alistair Wheeler
BACKGROUND: SUN-101 is a combination of glycopyrrolate delivered through an innovative, electronic nebulizer, intended for the treatment of patients with COPD. The objective of this study was to assess the efficacy and safety of this new drug device combination.
METHODS: Replicate Phase III randomized, double-blind, placebo-controlled studies were conducted to evaluate the efficacy and safety of glycopyrrolate solution administered by an investigational eFlow® Closed System (eFlow® CS) ...
| Known for Nebulized Glycopyrrolate | Electronic Nebulizer | 12 Weeks | Efficacy Safety | Severe Copd |
BACKGROUND: The use of long-acting bronchodilators is an essential component of the management of chronic obstructive pulmonary disease (COPD). The GOLDEN 5 Phase III, randomized, active-controlled, open-label study was conducted to evaluate the long-term safety and tolerability of a nebulized glycopyrrolate formulation (SUN-101) delivered via the investigational eFlow® Closed System (eFlow® CS) nebulizer in subjects with moderate-to-very-severe COPD.
METHODS: Subjects were randomized in ...
| Known for Severe Copd | Vaporizers Pulmonary Disease | Nebulized Glycopyrrolate | Incidence Teaes | Term Safety |
One-Year Safety and Efficacy Study of Arformoterol Tartrate in Patients With Moderate to Severe COPD
[ PUBLICATION ]
BACKGROUND: Arformoterol tartrate (arformoterol, 15 μg bid) is a nebulized long-acting β2-agonist approved for maintenance treatment of COPD.
METHODS: This was a multicenter, double-blind, randomized, placebo-controlled study. Patients (aged ≥ 40 years with baseline FEV1 ≤ 65% predicted, FEV1 > 0.50 L, FEV1/FVC ≤ 70%, and ≥ 15 pack-year smoking history) received arformoterol (n = 420) or placebo (n = 421) for 1 year. The primary assessment was time from randomization to respiratory death ...
| Known for Arformoterol Placebo | Severe Copd | 1 Year | Respiratory Death | Drug Administration |
In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
[ PUBLICATION ]
BACKGROUND: Glycopyrrolate administered by a novel, investigational eFlow® Closed System (CS) nebulizer (eFlow CS) is being evaluated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The eFlow CS is a hand-held, vibrating membrane nebulizer optimized to deliver 1 mL of glycopyrrolate solution into the lung in <3 minutes. Clinical studies have shown improvements in lung function of subjects treated with nebulized glycopyrrolate.
METHODS: The aerosol ...
| Known for Vaporizers Pulmonary Disease | Nebulized Glycopyrrolate | Eflow Closed | Inhalation Solution | Lung Function |
BackgroundLong-acting muscarinic antagonists (LAMAs) are recommended for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate/eFlow® is an investigational drug–device combination of the LAMA glycopyrrolate administered by an eFlow® Closed System (eFlow® CS) nebulizer. The GOLDEN 2 (NCT01706536) and GOLDEN 6 (NCT02038829) Phase II, multicenter studies were conducted to inform dose selection for the GOLDEN Phase III clinical trials. Bronchodilator responses and ...
| Known for Vaporizers Pulmonary Disease | Glycopyrrolate Eflow | Obstructive Lung | Phase Iii | 50 Μg |
Key People For Nebulized Glycopyrrolate
Alistair Wheeler:Expert Impact
Concepts for whichAlistair Wheelerhas direct influence:Nebulized glycopyrrolate, Vaporizers pulmonary disease, Severe copd, Arformoterol placebo, Obstructive lung disease, Arformoterol tartrate, Glycopyrrolate eflow, Electronic nebulizer.
Alistair Wheeler:KOL impact
Concepts related to the work of other authors for whichfor which Alistair Wheeler has influence:Nebulized glycopyrrolate, Patients copd, Pulmonary disease, Chronic obstructive, Small airways, Inhaled medications, Baseline rescue medication.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |